Cell Therapy for Chronic Traumatic Cervical Incomplete Spinal Cord Injury
Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, placebo-controlled, multicenter clinical trial in which
18 patients affected with chronic traumatic incomplete cervical spinal cord injury will be
randomized to either the active treatment (2 doses of intrathecal WJ-MSC 3 months apart) or
to placebo (2 intrathecal infusions, 3 months apart). Thereafter, patients will be
followed-up for 12 months for safety and efficacy assessment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Banc de Sang i Teixits
Collaborators:
Academic Research Organization (ARO) - VHIR Institut Guttmann